EGFR and metastatic colorectal cancer: Cetuximab: Cetuximab is an EGFR inhibitor, a fully humanized mAB, with FDA-approval for patients with K-Ras wild-type, EGFR-expressing colorectal cancer, metastatic colorectal cancer and advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.